We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+6.85%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$25.9M
Cap. Flow
+$19M
Cap. Flow %
10.03%
Top 10 Hldgs %
53.85%
Holding
93
New
27
Increased
23
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$2.5M
2
TPB icon
Turning Point Brands
TPB
+$1.88M
3
AMGN icon
Amgen
AMGN
+$1.6M
4
JNJ icon
Johnson & Johnson
JNJ
+$987K
5
IWM icon
iShares Russell 2000 ETF
IWM
+$588K

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$3.59M
2
BIIB icon
Biogen
BIIB
+$1.36M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$1.08M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$713K
5
NEM icon
Newmont
NEM
+$368K

Sector Composition

Rank Sector Weight
1 Healthcare 35.09%
2 Technology 14.46%
3 Communication Services 6.26%
4 Consumer Discretionary 3.14%
5 Energy 2.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JQC icon
26
Nuveen Credit Strategies Income Fund
JQC
$705M
$1.97M 1.04%
390,000
+26,000
+7% +$130K
GDXJ icon
27
VanEck Junior Gold Miners ETF
GDXJ
$6.89B
$1.78M 0.94%
50,000
+5,000
+11% +$194K
GM icon
28
General Motors
GM
$80.4B
$1.7M 0.9%
44,000
– –
BABA icon
29
Alibaba
BABA
$293B
$1.48M 0.78%
17,750
+5,150
+41% +$451K
PFE icon
30
Pfizer
PFE
$143B
$1.48M 0.78%
40,250
– –
VIR icon
31
Vir Biotechnology
VIR
$1.46B
$1.35M 0.71%
55,000
-7,000
-11% -$176K
F icon
32
Ford
F
$58.5B
$1.29M 0.68%
85,000
– –
LNSR icon
33
LENSAR
LNSR
$61.5M
$1.23M 0.65%
289,814
-60,928
-17% -$186K
VIR icon
34
CALL
Vir Biotechnology
VIR
$1.46B
$1.23M 0.65%
+50,100
New +$1.26M
MRVL icon
35
Marvell Technology
MRVL
$168B
$1.2M 0.63%
20,000
-2,500
-11% -$121K
CSCO icon
36
Cisco
CSCO
$457B
$1.16M 0.62%
22,500
+2,500
+13% +$123K
SLV icon
37
iShares Silver Trust
SLV
$28B
$1.04M 0.55%
50,000
– –
JNJ icon
38
Johnson & Johnson
JNJ
$618B
$1.01M 0.53%
+6,113
New +$987K
B
39
Barrick Mining
B
$61.5B
$889K 0.47%
52,500
+12,500
+31% +$228K
AMGN icon
40
CALL
Amgen
AMGN
$208B
$888K 0.47%
4,000
-400
-9% -$92.8K
VIR icon
41
PUT
Vir Biotechnology
VIR
$1.46B
$846K 0.45%
+34,500
New +$866K
LFCR icon
42
Lifecore Biomedical
LFCR
$166M
$846K 0.45%
+87,500
New +$534K
QCOM icon
43
Qualcomm
QCOM
$155B
$833K 0.44%
7,000
+2,000
+40% +$230K
STEW
44
SRH Total Return Fund
STEW
$1.79B
$784K 0.41%
59,000
– –
OI icon
45
O-I Glass
OI
$1.1B
$747K 0.39%
35,000
+23,500
+204% +$507K
MU icon
46
PUT
Micron Technology
MU
$930B
$726K 0.38%
11,500
+1,500
+15% +$96.4K
NOK icon
47
Nokia
NOK
$51B
$713K 0.38%
171,500
+21,500
+14% +$90.9K
PAAS icon
48
Pan American Silver
PAAS
$18.2B
$656K 0.35%
45,000
– –
AMZN icon
49
Amazon
AMZN
$2.92T
$652K 0.34%
5,000
– –
PANW icon
50
Palo Alto Networks
PANW
$270B
$639K 0.34%
+5,000
New +$520K
1
2
3 4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q2 2023 Portfolio in Review

As of Q2 2023, DCF Advisers held 93 positions worth $189M, up 16% from $163M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DCF Advisers deployed $19M of net new capital in Q2 2023, opening 27 new positions and adding to 23 existing holdings. Its largest new stake was Zimmer Biomet: 18,397 shares worth $2.68M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 40% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was AbbVie, an estimated $3.59M trimmed.

  • DCF Advisers's largest Q2 2023 buy was Zimmer Biomet: 18,397 shares worth $2.68M.
  • DCF Advisers added most to Amgen in Q2 2023, an estimated $1.6M increase.
  • DCF Advisers's biggest Q2 2023 reduction was AbbVie, cutting an estimated $3.59M.
  • DCF Advisers fully exited Biogen in Q2 2023, selling an estimated $1.36M.
  • DCF Advisers's ten largest holdings make up 54% of its $189M portfolio in Q2 2023.
  • DCF Advisers opened 27 new positions and closed 5 in Q2 2023.
  • DCF Advisers's portfolio value rose 16% quarter-over-quarter to $189M.

Based on DCF Advisers's 13F filing for Q2 2023, filed 9 Aug 2023.